About this trial

Patient Profile

Patients with melanoma who have had prior neo/adjuvant PD-(L)1 more than 6 months before enrolment

Where’s this trial being run?

St Vincents University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: R3767-ONC-1613
Number: CTRIAL-IE 20-11
Full Title:

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies

Principal Investigator: Ray McDermott
Type: Industry Sponsored


Recruitment Started: Global: Nov 2016
Ireland: 2019
Global Recruitment Target: 669
Ireland Recruitment Target: